The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

	UNITED STATES SECURIT	IES AND EXCHANG	E COMMISSION	OMB APPROVAL	
Washington, D.C. 20549 FORM D			OMB Number: 3235-0076 Estimated average burden hours per response: 4.00		
Notice of Exempt Offering of Securities					
1. Issuer's Identity					
CIK (Filer ID Number)	Previous Names	None	Entity Type		
0001815776	Integral Medi	icines Inc	X Corporation		
Name of Issuer		erapeutics Inc.	Limited Partnershi	n	
Graphite Bio, Inc.	-	-			
Jurisdiction of Incorporation/Org	ganization		Limited Liability Co		
DELAWARE			General Partnersh	ip	
Year of Incorporation/Organizat	tion		Business Trust		
Over Five Years Ago			Other (Specify)		
X Within Last Five Years (Spe	cify Year) 2019				
Yet to Be Formed					
2. Principal Place of Business	and Contact Information				
Name of Issuer					
Graphite Bio, Inc.					
Street Address 1		Street Address 2			
279 EAST GRAND AVENUE, SU					
City	State/Province/Country	ZIP/PostalCode	Phone Number of Is	suer	
SOUTH SAN FRANCISCO	CALIFORNIA	94080	(650) 484-0886		
3. Related Persons					
Last Name	First Name		Middle Name		
Lehrer	Josh				
Street Address 1	Street Address 2				
C/O GRAPHITE BIO, INC.		AVENUE, SUITE 430			
City SOUTH SAN FRANCISCO	State/Province/Co CALIFORNIA	burntry	ZIP/PostalCode 94080		
Relationship: X Executive Offic					
Clarification of Response (if Neo					
Last Name	First Name		Middle Name		
Stultz	Katherine				
Street Address 1	Street Address 2				
C/O GRAPHITE BIO, INC.	279 EAST GRAND	AVENUE, SUITE 430			
City	State/Province/Co		ZIP/PostalCode		
SOUTH SAN FRANCISCO	CALIFORNIA		94080		
Relationship: X Executive Offic	er Director Promoter				
Clarification of Response (if Neo	cessary):				
Last Name	First Name		Middle Name		
Gutry	Philip				
Street Address 1	Street Address 2				
C/O GRAPHITE BIO, INC.		AVENUE, SUITE 430			
City	State/Province/Co	ountry	ZIP/PostalCode		
SOUTH SAN FRANCISCO	CALIFORNIA		94080		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Karsen	Perry	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode
SOUTH SAN FRANCISCO	CALIFORNIA	94080
Relationship: Executive Officer X	Director	
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Davis	Jerel	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	7ID/DestalCade
City SOUTH SAN FRANCISCO	State/Province/Country CALIFORNIA	ZIP/PostalCode 94080
Relationship: Executive Officer X		54000
Clarification of Response (if Necessar		
,		
Last Name	First Name	Middle Name
Jimenez Street Address 1	Joe Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode
SOUTH SAN FRANCISCO	CALIFORNIA	94080
Relationship: Executive Officer X		21000
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Porteus	Matthew	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode
SOUTH SAN FRANCISCO	CALIFORNIA	94080
Relationship: Executive Officer X	Director	
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Rizzuto	Carlo	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode
SOUTH SAN FRANCISCO	CALIFORNIA	94080
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Roncarolo	Maria Grazia	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode
SOUTH SAN FRANCISCO Relationship: Executive Officer X E		94080
Clarification of Response (if Necessar		
Last Name	First Name	Middle Name
Bassan	Abraham	
Street Address 1	Street Address 2	
C/O GRAPHITE BIO, INC.	279 EAST GRAND AVENUE, SUITE 430	
City	State/Province/Country	ZIP/PostalCode

### SOUTH SAN FRANCISCO

94080

Clarification of Response (if Necessary):

Relationship: Executive Officer X Director Promoter

4.	Industry	Group

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	□ □ Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	
Investing		
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes	Construction	
Other Banking & Financial Services	REITS & Finance	Tourism & Travel Services
Business Services		Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		

## Other Energy

### 5. Issuer Size

Revenue Range	OR A	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company A	Investment Company Act Section 3(c)		
$\square Pulo 504(h)(1) (net(i), ii) er(iii))$	Section 3(c)(1)	Section 3(c)(9)		
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)		
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)		
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)		
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)		
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)		
	Section 3(c)(7)			

7. Type of Filing	
X New Notice Date of First Sale 2021-03-11 First Sale Yet to Occur	
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more than one year?	X No
9. Type(s) of Securities Offered (select all that apply)	
X Equity	Pooled Investment Fund Interests
	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other R Acquire Security	
10. Business Combination Transaction	
Is this offering being made in connection with a business combination tr or exchange offer?	ansaction, such as a merger, acquisition
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside investor $0$ USD	
12. Sales Compensation	
Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer 🛛 None	(Associated) Broker or Dealer CRD Number 🛛 None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US
13. Offering and Sales Amounts	
Total Offering Amount \$150,749,985 USD or Indefinite	
Total Amount Sold \$150,749,985 USD	
Total Remaining to be Sold \$0 USD or Indefinite	
Clarification of Response (if Necessary):	
14. Investors	
$\square$ such non-accredited investors who already have invested in the offe	ns who do not qualify as accredited investors, and enter the number of ring. e sold to persons who do not qualify as accredited investors, enter the
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders fees e check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known, provide an estimate and
Sales Commissions \$0 USD Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

#### Signature and Submission

## Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration go accept service of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Graphite Bio, Inc.	/s/ Josh Lehrer	Josh Lehrer	Chief Executive Officer	2021-03-19

# Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.